S&P 500 · sector · 60 bedrijven
Aandelen uit de sector Gezondheidszorg in de S&P 500
In hun laatste boekjaren hadden de bedrijven uit de sector samen $3,66 bln. omzet en $196 mld. nettowinst (5,4% van de omzet). Het grootste naar omzet is UnitedHealth Group.
Gezamenlijke omzet in het laatste boekjaar, 60 bedrijven
$3,66 bln.+9,1% per jaar
mediane omzetgroei over 10 jaar (53 bedrijven)
Bedrijven
60
subsectoren: 10
Gezamenlijke nettowinst
$196 mld.
5,4% omzet
Mediane nettomarge
13,0%
laatste boekjaar
Keren dividend uit
37 van 60
verhoogden het elk jaar in de gegevens: 7 bedrijven
Minder aandelen dan 10 jaar geleden
31 van 57
mediane verandering −5,8%
Gezamenlijke omzet en nettowinst sinds 2010
De omzet van de bedrijven met cijfers voor elk jaar (48) ging van $980 mld. in 2010 naar $3,33 bln. in 2025, 8,5% per jaar.
OmzetNettowinst
De grafiekgegevens konden niet worden geladen. De tabel hieronder bevat dezelfde cijfers.
Bedrijven
| UnitedHealth Group | UNH | Managed Health Care | 2025 | $448 mld. | $12,1 mld. | 2,7% | 11,7% | 11,0% | 8,2% | $8,73 | 16 | −5,8% |
| McKesson | MCK | Health Care Distributors | 2026 | $403 mld. | $4,76 mld. | 1,2% | 11,1% | 7,8% | 14,7% | $3,17 | 13 | −46,7% |
| CVS Health | CVS | Health Care Services | 2025 | $402 mld. | $1,77 mld. | 0,4% | 8,4% | 10,1% | −11,3% | $2,66 | 0 | +12,9% |
 Cencora | COR | Health Care Distributors | 2025 | $321 mld. | $1,55 mld. | 0,5% | 11,1% | 9,0% | — | $2,20 | 17+ | −10,4% |
| Cigna | CI | Health Care Services | 2025 | $275 mld. | $5,96 mld. | 2,2% | 11,4% | 21,9% | 10,7% | $6,04 | 5 | +3,1% |
 Cardinal Health | CAH | Health Care Distributors | 2026 | $254 mld. | $1,71 mld. | 0,7% | 9,4% | 7,7% | 5,3% | $2,04 | 18+ | −28,2% |
 Elevance Health | ELV | Managed Health Care | 2025 | $199 mld. | $5,66 mld. | 2,8% | 10,3% | 9,7% | 10,4% | $6,84 | 14 | −17,7% |
 Centene Corporation | CNC | Managed Health Care | 2025 | $195 mld. | −$6,67 mld. | −3,4% | 11,9% | 23,9% | — | — | — | +100,3% |
 Humana | HUM | Managed Health Care | 2025 | $130 mld. | $1,19 mld. | 0,9% | 10,9% | 9,1% | 1,5% | $3,54 | 0 | −20,1% |
| Johnson & Johnson | JNJ | Pharmaceuticals | 2025 | $94,2 mld. | $26,8 mld. | 28,5% | 2,7% | 3,0% | 7,2% | $5,14 | 18+ | −13,6% |
 HCA Healthcare | HCA | Health Care Facilities | 2025 | $75,6 mld. | $6,78 mld. | 9,0% | 8,0% | — | 19,0% | $2,88 | 5 | −43,9% |
 Lilly (Eli) | LLY | Pharmaceuticals | 2025 | $65,2 mld. | $20,6 mld. | 31,7% | 21,6% | 12,6% | 26,1% | $6,23 | 9 | −15,6% |
 Merck & Co. | MRK | Pharmaceuticals | 2025 | $65 mld. | $18,3 mld. | 28,1% | 9,4% | 5,1% | 16,7% | $3,28 | 15 | −11,8% |
 Pfizer | PFE | Pharmaceuticals | 2025 | $62,6 mld. | $7,77 mld. | 12,4% | 8,5% | 2,5% | 2,1% | $1,72 | 15 | −8,7% |
 AbbVie | ABBV | Biotechnology | 2025 | $61,2 mld. | $4,23 mld. | 6,9% | 6,0% | 10,3% | −2,8% | $6,65 | 11 | +8,3% |
 Bristol Myers Squibb | BMY | Pharmaceuticals | 2025 | $48,2 mld. | $7,05 mld. | 14,6% | 2,5% | 11,3% | 14,0% | $2,49 | 18+ | +21,4% |
 Thermo Fisher Scientific | TMO | Life Sciences Tools & Services | 2025 | $44,6 mld. | $6,7 mld. | 15,0% | 6,7% | 10,1% | 13,7% | $1,72 | 8 | −6,0% |
 Abbott Laboratories | ABT | Health Care Equipment | 2025 | $44,3 mld. | $6,52 mld. | 14,7% | 5,1% | 8,1% | 2,5% | $2,40 | 3 | +16,1% |
 Amgen | AMGN | Biotechnology | 2025 | $36,8 mld. | $7,71 mld. | 21,0% | 7,6% | 5,4% | 4,6% | $9,66 | 12 | −29,2% |
 Medtronic | MDT | Health Care Equipment | 2026 | $36,4 mld. | $4,8 mld. | 13,2% | 3,8% | 2,3% | 4,2% | $2,84 | 18+ | −9,7% |
| Gilead Sciences | GILD | Biotechnology | 2025 | $29,4 mld. | $8,51 mld. | 28,9% | 3,6% | −1,0% | −5,5% | $3,16 | 10 | −17,5% |
 Stryker Corporation | SYK | Health Care Equipment | 2025 | $25,1 mld. | $3,25 mld. | 12,9% | 11,8% | 9,7% | 8,3% | $3,40 | 16 | +1,5% |
 Danaher Corporation | DHR | Life Sciences Tools & Services | 2025 | $24,6 mld. | $3,61 mld. | 14,7% | 2,0% | — | 0,6% | — | — | +1,1% |
 Becton Dickinson | BDX | Health Care Equipment | 2025 | $21,8 mld. | $1,68 mld. | 7,7% | 6,3% | 7,8% | 5,7% | $4,16 | 12 | +39,0% |
| GE HealthCare | GEHC | Health Care Equipment | 2025 | $20,6 mld. | $2,08 mld. | 10,1% | — | — | — | $0,14 | 2+ | — |
 Boston Scientific | BSX | Health Care Equipment | 2025 | $20,1 mld. | $2,9 mld. | 14,4% | 15,2% | 10,4% | — | — | — | +11,4% |
 Universal Health Services | UHS | Health Care Facilities | 2025 | $17,4 mld. | $1,49 mld. | 8,6% | 8,5% | 6,7% | 13,1% | $0,80 | 0 | −36,0% |
 IQVIA | IQV | Life Sciences Tools & Services | 2025 | $16,3 mld. | $1,36 mld. | 8,3% | 7,5% | 11,0% | 9,8% | — | — | +38,1% |
| Regeneron Pharmaceuticals | REGN | Biotechnology | 2025 | $14,3 mld. | $4,5 mld. | 31,4% | 11,0% | 13,3% | 22,3% | $3,52 | 0 | −5,8% |
 Viatris | VTRS | Pharmaceuticals | 2025 | $14,3 mld. | −$3,51 mld. | −24,6% | 3,7% | 4,3% | — | $0,48 | 0 | +134,6% |
| Labcorp | LH | Health Care Services | 2025 | $14 mld. | $876 mln. | 6,3% | −0,0% | 4,9% | 9,2% | $2,88 | 0 | −16,7% |
 DaVita | DVA | Health Care Services | 2025 | $13,6 mld. | $747 mln. | 5,5% | 3,4% | — | 22,9% | — | — | −64,9% |
| Henry Schein | HSIC | Health Care Distributors | 2025 | $13,2 mld. | $398 mln. | 3,0% | 5,4% | — | 1,4% | — | — | −27,7% |
 Vertex Pharmaceuticals | VRTX | Biotechnology | 2025 | $12 mld. | $3,95 mld. | 32,9% | 14,1% | 27,8% | — | — | — | +6,9% |
 Baxter International | BAX | Health Care Equipment | 2025 | $11,2 mld. | −$957 mln. | −8,5% | −0,7% | 1,2% | — | $0,52 | 0 | −6,6% |
| Quest Diagnostics | DGX | Health Care Services | 2025 | $11 mld. | $992 mln. | 9,0% | 3,2% | 3,9% | 6,0% | $3,20 | 15 | −22,1% |
 Intuitive Surgical | ISRG | Health Care Equipment | 2025 | $10,1 mld. | $2,86 mld. | 28,4% | 18,2% | 15,5% | 16,4% | — | — | +6,3% |
| Biogen | BIIB | Biotechnology | 2025 | $9,89 mld. | $1,29 mld. | 13,1% | −6,0% | −0,8% | −5,4% | — | — | −36,4% |
 Zoetis | ZTS | Pharmaceuticals | 2025 | $9,47 mld. | $2,67 mld. | 28,2% | 7,2% | 7,1% | 24,4% | $2,03 | 12 | −11,6% |
 Solventum | SOLV | Health Care Technology | 2025 | $8,32 mld. | $1,56 mld. | 18,7% | — | — | — | — | — | — |
 Zimmer Biomet | ZBH | Health Care Equipment | 2025 | $8,23 mld. | $705 mln. | 8,6% | 6,1% | 3,2% | 16,5% | $0,96 | 0 | +4,7% |
 Agilent Technologies | A | Life Sciences Tools & Services | 2025 | $6,95 mld. | $1,3 mld. | 18,8% | 5,4% | 5,6% | 14,3% | $0,99 | 10 | −14,9% |
 Edwards Lifesciences | EW | Health Care Equipment | 2025 | $6,07 mld. | $1,07 mld. | 17,7% | 6,7% | 9,3% | 9,3% | — | — | −11,4% |
 Steris | STE | Health Care Equipment | 2026 | $5,94 mld. | $782 mln. | 13,2% | 13,8% | 10,2% | 17,7% | $2,46 | 15 | +38,7% |
 ResMed | RMD | Health Care Equipment | 2026 | $5,65 mld. | $1,52 mld. | 26,9% | 12,1% | 11,9% | 15,4% | $2,40 | 5 | +3,1% |
 Incyte | INCY | Biotechnology | 2025 | $5,14 mld. | $1,29 mld. | 25,0% | 14,0% | 21,2% | 71,0% | — | — | +7,2% |
| Dexcom | DXCM | Health Care Equipment | 2025 | $4,66 mld. | $836 mln. | 17,9% | 19,3% | 27,8% | — | — | — | +27,0% |
 Illumina, Inc. | ILMN | Life Sciences Tools & Services | 2025 | $4,34 mld. | $850 mln. | 19,6% | 6,0% | 6,9% | 5,8% | — | — | +4,7% |
 Idexx Laboratories | IDXX | Health Care Equipment | 2025 | $4,3 mld. | $1,06 mld. | 24,6% | 9,7% | 10,4% | 20,4% | — | — | −13,5% |
 Cooper Companies (The) | COO | Health Care Supplies | 2025 | $4,09 mld. | $375 mln. | 9,2% | 11,0% | 8,6% | 6,1% | — | — | +1,6% |
 Align Technology | ALGN | Health Care Supplies | 2025 | $4,03 mld. | $410 mln. | 10,2% | 10,3% | 16,9% | 12,3% | — | — | −11,0% |
 Mettler Toledo | MTD | Life Sciences Tools & Services | 2025 | $4,03 mld. | $869 mln. | 21,6% | 5,5% | 5,3% | 12,9% | — | — | −26,9% |
 Charles River Laboratories | CRL | Life Sciences Tools & Services | 2025 | $4,02 mld. | −$144 mln. | −3,6% | 6,5% | 11,4% | — | — | — | +4,1% |
 Veeva Systems | VEEV | Health Care Technology | 2026 | $3,2 mld. | $909 mln. | 28,4% | 16,9% | 22,8% | 30,5% | — | — | +15,2% |
| Waters Corporation | WAT | Life Sciences Tools & Services | 2025 | $3,17 mld. | $643 mln. | 20,3% | 6,0% | 4,5% | 6,7% | — | — | −28,1% |
| West Pharmaceutical Services | WST | Health Care Supplies | 2025 | $3,07 mld. | $494 mln. | 16,1% | 7,4% | 8,2% | 18,0% | $0,86 | 17+ | −1,5% |
 Revvity | RVTY | Health Care Equipment | 2025 | $2,86 mld. | $241 mln. | 8,4% | 1,4% | 3,1% | 1,0% | $0,28 | 0 | +2,9% |
| Insulet Corporation | PODD | Health Care Equipment | 2025 | $2,71 mld. | $247 mln. | 9,1% | 24,5% | 26,2% | — | — | — | +26,6% |
 Moderna | MRNA | Biotechnology | 2025 | $1,94 mld. | −$2,82 mld. | −145,2% | 19,3% | — | — | — | — | — |
| Bio-Techne | TECH | Life Sciences Tools & Services | 2026 | $1,22 mld. | $182 mln. | 15,0% | 5,5% | 9,3% | 5,2% | $0,32 | 0 | +5,2% |
Omzet en nettowinst: het laatste volledige boekjaar. Groei: gemiddeld jaarlijks percentage over 5 of 10 jaar. Dividend: per aandeel in het laatste jaar. Verhogingen op rij: opeenvolgende jaren met een hoger dividend per aandeel; de SEC-gegevens beginnen in 2009 (met 2007–2008 als vergelijkingsjaren), dus + betekent een reeks die teruggaat tot het begin van de cijfers van het bedrijf. Aandelen, 10 jr: verandering in het aantal aandelen; onder nul betekent inkoop van eigen aandelen. —: niet in de gegevens of niet zinvol.
Andere sectoren
Bron: SEC EDGAR (bedrijfsdocumenten), gegevens per 13 november 2026. Sectoren, subsectoren, hoofdkantoren en indexdata: Wikipedia, CC BY-SA 4.0.